Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

Novartis launch NET cancer community app

Galaxies of Hope aims to provide support to cancer patients

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Inizio

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...

Inizio

- PMLiVE

Healthcare Comms news

Owen Health reveals UK pharma's social media ranking, Emotive presents scientific engagement award and Random42 wins a Golden Eagle award

Shift to preventative healthcare – Opportunities for screening, diagnostics and vaccination

Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...

Inizio

Conference Live for ongoing congress performance measurement

Director John Branston discusses the benefits of a mobile approach for evaluating medical conferences year-on-year

Inizio

Eyeforpharma Real World Evidence Conference Round up 2018

Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)This year has seen a turning point...

Inizio

- PMLiVE

MaxCyte gets green light for solid tumour cell therapy

Its first CAR therapy will be tested in patients with ovarian cancer

- PMLiVE

‘Common Rulebook’ Brexit plans include medicines – but face backlash

Government compromises could be opposed from both sides

- PMLiVE

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare

- PMLiVE

Novartis rejects claims it misled Senate over Cohen links

Report says Novartis discussed drug-pricing with the President’s former ‘fixer’

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links